NCT02116257

The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Yonsei University · Academic / Other
• Sex: Female
• Age: 20 Years – 65 Years
• Healthy volunteers: Accepted

Summary

While Patient-controlled analgesia (PCA) has the advantage of effectively reducing the degree of postoperative pain, it can also affect the patient's outcome by several adverse effects such as postoperative nausea and vomiting (PONV). Especially for high risk group of patients for PONV, the ideal regimen for sufficient analgesia with minimal adverse effect needs to be sought. Propacetamol is known for its effective, rapid analgesia, opioid-sparing effect, and is used widely for post operative pain management. This study aims to see the opioid-sparing effect and the degree of PONV when propacetamol is added to PCA for high risk PONV patients.

Conditions

• PONV
• Propacetamol

Interventions

Type	Name	Description
DRUG	Propacetamol	total 4g of Propacetamol added to patient's PCA regimen
DRUG	PCA regimen

Timeline

• Start date: 2013-11-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2014-04-16
• Last updated: 2015-06-24

Locations

1 site across 1 country: South Korea